Corvus Pharmaceuticals

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the treatment of immune diseases and cancer through innovative approaches like ITK inhibition.

Products & Services

Soquelitinib:A first-in-class, oral therapy that selectively inhibits ITK to modulate and control parallel signaling pathways in the immune system.

Specialties

ITK inhibition Immune system modulation Therapies for immune diseases and cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 201200000 MR: - FA: approximately $201.2 million FAN: 201200000	D: 2026-01-23 FD: 2026-01-23	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: approximately $175.0 million FAN: 175000000	D: 2026-01-21 FD: 2026-01-21	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150,000,000 FAN: 150000000	D: 2026-01-20 FD: 2026-01-20	4 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 30600000 MR: - FA: 30.6 million FAN: 30600000	D: 2024-05-02 FD: 2024-05-02	7 investors

Public Offering Latest

2026-01-23

$201.2M

4 investors (Pro only)

Public Offering 2026-01-21

$175.0M

Public Offering 2026-01-20

$150.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard A. Miller

President and CEO, Co-Founder

L

Leiv Lea

CHIEF FINANCIAL OFFICER

J

Jeffrey Arcara

Chief Business Officer

O

Otute Akiti

Vice President, CMC

W

William Ben Jones

SENIOR VICE PRESIDENT, PHARMACEUTICAL DEVELOPMENT

G

Gabriel Luciano

Vice President Clinical Operations

View 10 more team members with Pro

Unlock Full Team Directory

Recent News